Immunome Inc. Common Stock (IMNM)

About IMNM

Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan r…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

247

Website

immunome.com/

Fundamentals

1-day range

$27.63$30.06

Market cap

$2.92B

P/E (trailing)

—

P/E (forward)

-12.03

EPS (trailing)

$-2.36

Dividend yield

—

Beta

2.54

Avg. volume

1.39M

Forecasts

13 analyst ratings

Immunome Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• IMNM

  Immunome Inc. Common Stock

  $27.57

  ▼ 4.50%
  Market cap $2.92BP/E —
  $8.67$30.06
• IRON

  Disc Medicine Inc. Common Stock

  $80.01

  ▼ 3.08%
  Market cap $2.97BP/E —
  $40$99.5
• SUPN

  Supernus Pharmaceuticals Inc. Common Stock

  $43.76

  ▼ 0.97%
  Market cap $2.72BP/E —
  $42.45$59.68
• MBX

  MBX Biosciences Inc. Common Stock

  $63.04

  ▼ 5.05%
  Market cap $3.19BP/E —
  $9.63$72.64
• TRVI

  Trevi Therapeutics Inc. Common Stock

  $16.78

  ▼ 6.60%
  Market cap $2.63BP/E —
  $6.93$20.22
• NRIX

  Nurix Therapeutics Inc. Common stock

  $26.19

  ▼ 2.57%
  Market cap $2.62BP/E —
  $8.2$28.23
• NAMS

  NewAmsterdam Pharma Company N.V. Ordinary Shares

  $25.9

  ▼ 3.32%
  Market cap $3.23BP/E —
  $23.05$42.21

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Immunome: Maintaining My 'Strong Buy' Rating With 2 Catalysts On The Horizon
  SeekingAlpha · 8/13/2026
• Truist Securities Maintains Buy on Immunome, Raises Price Target to $38
  benzinga · 8/12/2026
• Truist Securities Maintains Buy on Immunome, Raises Price Target to $38
  Benzinga · 8/12/2026
• Wedbush Maintains Outperform on Immunome, Raises Price Target to $35
  Benzinga · 8/12/2026
• Immunome Q2 EPS $(0.65) Misses $(0.52) Estimate
  Benzinga · 8/11/2026
• The BioRevolution Has Accelerated
  SeekingAlpha · 8/5/2026
• SpaceX, Teradata, Pinterest And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
  Benzinga · 8/5/2026

• Isaac Barchas · August 12, 2026 · Sale

  11.0K @ $27.25
• Isaac Barchas · August 11, 2026 · Sale

  62.3K @ $26.23
• Isaac Barchas · August 10, 2026 · Sale

  10.1K @ $26.07
• Isaac Barchas · August 7, 2026 · Sale

  15.2K @ $26.06
• Isaac Barchas · August 6, 2026 · Sale

  20.8K @ $26.06
• Kinney Horn · August 4, 2026 · Option Exercise

  40.3K @ $10.6
• Kinney Horn · August 4, 2026 · Option Exercise

  50.4K @ $12.92
• Kinney Horn · August 4, 2026 · Sale

  90.6K @ $25.09
• Philip Tsai · July 23, 2026 · Grant

  76.5K
• Philip Tsai · July 23, 2026 · Grant

  38.3K
• Robert Lechleider · July 23, 2026 · Grant

  108.0K
• Robert Lechleider · July 23, 2026 · Grant

  54.0K
• Max Rosett · July 23, 2026 · Grant

  94.5K
• Max Rosett · July 23, 2026 · Grant

  47.3K
• Jack Higgins · July 23, 2026 · Grant

  76.5K

Institutional Ownership

March 31, 2026

Total shares held

113.55M

Total value held

$2.06B

Institutional holders

193